Geert Nygaard has taken on the CEO role at Glycorex Transplantation, starting in the position as of December 15. Glycorex has developed a molecular level nanosurgical technology that specifically selects and removes antibodies in the blood, which has opened up new solutions in transplantation, management of blood donor blood and treatment of autoimmune diseases.
Nygaard has over 30 years of experience in the diagnostics and life science markets having served in a variety of senior leadership roles with Abbott Laboratories, TECAN, Epigenomics and DAKO.
After more than 20 years working abroad, he has returned to Denmark. His international experience brings regulatory and quality expertise, having led a publicly listed company and getting FDA approval in the US.
Kurt Nilsson, Chairman of Glycorex Transplantation said: “His background and experience make him well suited to expand and guide the company through its important next phase, that is planning and conducting a clinical study in the US, commercialising our UBP-product and obtaining a CE-mark for our RA-product”.